{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:06:14Z","timestamp":1789542374732,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL132011-01"],"award-info":[{"award-number":["K23HL132011-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR000113-05"],"award-info":[{"award-number":["KL2TR000113-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Minnesota Clinical and Translational Science Institute"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","geriatriconcology.net","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jgo.2017.04.001","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T19:11:09Z","timestamp":1494357069000},"page":"308-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Cardio-oncology in the older adult"],"prefix":"10.1016","volume":"8","author":[{"given":"Prajwal","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne H.","family":"Blaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jgo.2017.04.001_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.jgo.2017.04.001_bb0010","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/1055-9965.EPI-11-0729","article-title":"Cancer survivors: a booming population","volume":"20","author":"Parry","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.jgo.2017.04.001_bb0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1055-9965.EPI-12-1356","article-title":"Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care","volume":"22","author":"de Moor","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jgo.2017.04.001_bb0020","doi-asserted-by":"crossref","DOI":"10.5888\/pcd13.160211","article-title":"Heart disease and cancer deaths\u2014trends and projections in the United States, 1969\u20132020","volume":"13","author":"Weir","year":"2016","journal-title":"Prev Chronic Dis"},{"issue":"21","key":"10.1016\/j.jgo.2017.04.001_bb0025","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/CIR.0000000000000380","article-title":"Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society","volume":"133","author":"Rich","year":"2016","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.jgo.2017.04.001_bb0030","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jgo.2017.04.001_bb0035","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1634\/theoncologist.2011-0384","article-title":"A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316)","volume":"17","author":"Javid","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2017.04.001_bb0040","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s12885-015-1947-9","article-title":"Under-treatment of elderly patients with ovarian cancer: a population based study","volume":"15","author":"Fourcadier","year":"2015","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.jgo.2017.04.001_bb0045","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa0810266","article-title":"Adjuvant chemotherapy in older women with early-stage breast cancer","volume":"360","author":"Muss","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2017.04.001_bb0050","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","author":"Armenian","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jgo.2017.04.001_bb0055","author":"Centers for Disease Control and Prevention"},{"issue":"1","key":"10.1016\/j.jgo.2017.04.001_bb0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jgo.2015.10.182","article-title":"Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML)","volume":"7","author":"Tawfik","year":"2016","journal-title":"J Geriatr Oncol."},{"issue":"8","key":"10.1016\/j.jgo.2017.04.001_bb0065","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1634\/theoncologist.2010-0348","article-title":"Cardiovascular complications of breast cancer therapy in older adults","volume":"16","author":"Shenoy","year":"2011","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.jgo.2017.04.001_bb0070","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00520-014-2171-x","article-title":"Prevalence and factors associated with polypharmacy in older people with cancer","volume":"22","author":"Turner","year":"2014","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.jgo.2017.04.001_bb0075","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11096-014-0029-4","article-title":"Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience","volume":"36","author":"Lopez-Martin","year":"2014","journal-title":"Int J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jgo.2017.04.001_bb0080","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jgo.2014.07.001","article-title":"Potentially inappropriate medication use in older people with cancer: prevalence and correlates","volume":"5","author":"Saarelainen","year":"2014","journal-title":"J Geriatr Oncol."},{"issue":"5","key":"10.1016\/j.jgo.2017.04.001_bb0085","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00520-012-1661-y","article-title":"The impact of medication therapy management in older oncology patients","volume":"21","author":"Yeoh","year":"2013","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2017.04.001_bb0090","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jgo.2015.05.001","article-title":"Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy","volume":"6","author":"Yeoh","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"24","key":"10.1016\/j.jgo.2017.04.001_bb0095","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2013.55.0459","article-title":"Cardiac effects of anticancer therapy in the elderly","volume":"32","author":"Accordino","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2017.04.001_bb0100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s13670-015-0147-4","article-title":"The Crossroads of geriatric cardiology and cardio-oncology","volume":"4","author":"Nguyen","year":"2015","journal-title":"Current Geriatrics Reports"},{"key":"10.1016\/j.jgo.2017.04.001_bb0105","series-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","first-page":"1471","author":"Smith","year":"2010"},{"issue":"14","key":"10.1016\/j.jgo.2017.04.001_bb0110","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jgo.2017.04.001_bb0115","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.jgo.2017.04.001_bb0120","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jgo.2017.04.001_bb0125","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jgo.2017.04.001_bb0130","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.amjcard.2012.07.040","article-title":"Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines","volume":"110","author":"Neilan","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jgo.2017.04.001_bb0135","series-title":"Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper","first-page":"1569","author":"Aapro","year":"2010"},{"issue":"3","key":"10.1016\/j.jgo.2017.04.001_bb0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2014.09.001","article-title":"Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial","volume":"15","author":"Oki","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.jgo.2017.04.001_bb0145","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-015-3415-2","article-title":"Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study","volume":"151","author":"Gil-Gil","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.jgo.2017.04.001_bb0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3324\/haematol.2010.027862","article-title":"A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study","volume":"96","author":"Hunault-Berger","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2017.04.001_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003917.pub4","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"6","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jgo.2017.04.001_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw671","article-title":"Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis","author":"Abdel-Qadir","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2017.04.001_bb0165","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2017.04.001_bb0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ctrv.2009.06.007","article-title":"Trastuzumab versus lapatinib: the cardiac side of the story","volume":"35","author":"Azim","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"33","key":"10.1016\/j.jgo.2017.04.001_bb0175","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","article-title":"Trastuzumab-related cardiotoxicity among older patients with breast cancer","volume":"31","author":"Chavez-MacGregor","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2017.04.001_bb0180","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1517\/14740338.2015.1089231","article-title":"Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data","volume":"14","author":"Leung","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.jgo.2017.04.001_bb0185","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial","volume":"34","author":"Advani","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2017.04.001_bb0190","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","article-title":"Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)","volume":"26","author":"Mavroudis","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2017.04.001_bb0195","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","article-title":"6months versus 12months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jgo.2017.04.001_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012798","article-title":"Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer","volume":"6","author":"Polk","year":"2016","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jgo.2017.04.001_bb0205","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.jgo.2017.04.001_bb0210","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.jgo.2017.04.001_bb0215","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1185\/03007995.2013.807232","article-title":"Cardiotoxicity of novel HER2-targeted therapies","volume":"29","author":"Sendur","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.jgo.2017.04.001_bb0220","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000369256","article-title":"Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial","volume":"88","author":"Sternberg","year":"2015","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.jgo.2017.04.001_bb0225","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/eci.12589","article-title":"Update on cardiotoxicity of anti-cancer treatments","volume":"46","author":"Rosa","year":"2016","journal-title":"Eur J Clin Invest"},{"issue":"9604","key":"10.1016\/j.jgo.2017.04.001_bb0230","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jgo.2017.04.001_bb0235","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4330\/wjc.v8.i9.504","article-title":"Novel concepts in radiation-induced cardiovascular disease","volume":"8","author":"Cuomo","year":"2016","journal-title":"World J Cardiol"},{"issue":"11","key":"10.1016\/j.jgo.2017.04.001_bb0240","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jgo.2017.04.001_bb0245","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jnci\/dji067","article-title":"Risk of cardiac death after adjuvant radiotherapy for breast cancer","volume":"97","author":"Giordano","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.jgo.2017.04.001_bb0250","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2007.12.006","article-title":"Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program","volume":"66","author":"Basso","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"10.1016\/j.jgo.2017.04.001_bb0255","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.2006.10.3291","article-title":"Multidisciplinary approach to the geriatric oncology patient","volume":"25","author":"Terret","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2017.04.001_bb0260","article-title":"Abridged geriatric assessment is a better predictor of overall survival than the Karnofski Performance Scale and Physical Performance Test in elderly cancer patients","author":"Ghosn","year":"2016","journal-title":"J Geriatr Oncol."},{"issue":"24","key":"10.1016\/j.jgo.2017.04.001_bb0265","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2017.04.001_bb0270","author":"National Comprehensive Cancer Network"},{"issue":"5","key":"10.1016\/j.jgo.2017.04.001_bb0275","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ejso.2015.01.028","article-title":"Treatment patterns of elderly breast cancer patients at two Canadian cancer centres","volume":"41","author":"Angarita","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2017.04.001_bb0280","first-page":"355","article-title":"Cardiac toxicity of trastuzumab in elderly patients with breast cancer","volume":"13","author":"Denegri","year":"2016","journal-title":"J Geriatr Cardiol"},{"issue":"6","key":"10.1016\/j.jgo.2017.04.001_bb0285","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/annonc\/mdv018","article-title":"Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary","volume":"26","author":"Morrison","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2017.04.001_bb0290","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s002770100315","article-title":"The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates","volume":"80","author":"Peters","year":"2001","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jgo.2017.04.001_bb0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hon.2900110106","article-title":"COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma","volume":"11","author":"Liang","year":"1993","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2017.04.001_bb0300","first-page":"418","article-title":"Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma","volume":"143","author":"Sonneveld","year":"1999","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"10","key":"10.1016\/j.jgo.2017.04.001_bb0305","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1995.13.10.2530","article-title":"Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy","volume":"13","author":"Sonneveld","year":"1995","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2017.04.001_bb0310","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2014.06.026","article-title":"Utility of prechemotherapy evaluation of left ventricular function for patients with lymphoma","volume":"15","author":"Steuter","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.jgo.2017.04.001_bb0315","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/heartjnl-2015-307894","article-title":"Roadmap for biomarkers of cancer therapy cardiotoxicity","volume":"102","author":"Yu","year":"2016","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.jgo.2017.04.001_bb0325","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"23","key":"10.1016\/j.jgo.2017.04.001_bb0330","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jgo.2017.04.001_bb0335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial","volume":"134","author":"Tashakori Beheshti","year":"2016","journal-title":"Cardiology"},{"issue":"4","key":"10.1016\/j.jgo.2017.04.001_bb0340","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2459\/JCM.0000000000000232","article-title":"Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction","volume":"17","author":"Di Lisi","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"5","key":"10.1016\/j.jgo.2017.04.001_bb0345","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J"},{"issue":"23","key":"10.1016\/j.jgo.2017.04.001_bb0350","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jgo.2017.04.001_bb0355","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jgo.2017.04.001_bb0360","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s11897-014-0214-8","article-title":"Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab","volume":"11","author":"Gulati","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jgo.2017.04.001_bb0365","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","author":"Pituskin","year":"2016","journal-title":"J Clin Oncol."},{"issue":"13","key":"10.1016\/j.jgo.2017.04.001_bb0370","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.jgo.2017.04.001_bb0400","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/CIRCULATIONAHA.111.021774","article-title":"Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms","volume":"124","author":"Scott","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jgo.2017.04.001_bb0405","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-013-2808-3","article-title":"The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer","volume":"143","author":"Sturgeon","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"10.1016\/j.jgo.2017.04.001_bb0410","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1158\/1078-0432.CCR-09-0628","article-title":"Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training","volume":"15","author":"Haykowsky","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.jgo.2017.04.001_bb0415","first-page":"S1","article-title":"NCCN task force report: adjuvant therapy for breast cancer","volume":"4","author":"Carlson","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.jgo.2017.04.001_bb0420","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/hrt.2009.173997","article-title":"Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study","volume":"96","author":"Ho","year":"2010","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.jgo.2017.04.001_bb0425","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jgo.2017.04.001_bb0430","article-title":"Progressive 3-month increase in LV myocardial ECV after anthracycline-based chemotherapy","author":"Melendez","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.jgo.2017.04.001_bb0475","doi-asserted-by":"crossref","DOI":"10.1186\/s12968-017-0348-4","article-title":"Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance","volume":"19","author":"Huang","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jgo.2017.04.001_bb0435","doi-asserted-by":"crossref","DOI":"10.1007\/s12350-016-0540-1","article-title":"Frequent MUGA testing in a myeloma patient: a case-based ethics discussion","author":"Bhatti","year":"2016","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"10.1016\/j.jgo.2017.04.001_bb0440","first-page":"e67","article-title":"Troponin I and B-type natriuretic peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab","volume":"166","author":"Pistillucci","year":"2015","journal-title":"Clin Ter"},{"issue":"10","key":"10.1016\/j.jgo.2017.04.001_bb0445","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1200\/JCO.2010.30.3404","article-title":"Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes","volume":"30","author":"Lipshultz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2017.04.001_bb0450","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pcad.2010.04.002","article-title":"Role of biomarkers in chemotherapy-induced cardiotoxicity","volume":"53","author":"Cardinale","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"issue":"22","key":"10.1016\/j.jgo.2017.04.001_bb0455","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.jgo.2017.04.001_bb0460","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2017.04.001_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096736","article-title":"BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography","volume":"9","author":"Skovgaard","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jgo.2017.04.001_bb0470","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1053-2498(01)00776-8","article-title":"ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary","volume":"21","author":"Hunt","year":"2002","journal-title":"J Heart Lung Transplant"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406817300656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406817300656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T05:25:53Z","timestamp":1602048353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406817300656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1879406817300656"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2017.04.001","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardio-oncology in the older adult","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2017.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}